A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.

[1]  A. Maraval,et al.  Central nervous system involvement of primary cutaneous diffuse large B‐cell lymphoma, leg type: 13 cases , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  Esther J Kim,et al.  Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome. , 2017, The Journal of investigative dermatology.

[3]  F. Jardin,et al.  Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. , 2017, The Journal of investigative dermatology.

[4]  C. Deng,et al.  Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79 , 2017, Haematologica.

[5]  R. Greil,et al.  Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Staudt,et al.  A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2017, Clinical Cancer Research.

[7]  P. Zinzani,et al.  The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study , 2017, Leukemia & lymphoma.

[8]  S. Cuzzocrea,et al.  Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? , 2016, The oncologist.

[9]  F. Gall,et al.  MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. , 2016, The Journal of investigative dermatology.

[10]  J. Tuscano,et al.  A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma , 2016, Therapeutic advances in hematology.

[11]  H. Tun,et al.  Excellent Outcome of Immunomodulation or Bruton’s Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type , 2015, Rare tumors.

[12]  Roland Schmitz,et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.

[13]  Jun Wu,et al.  Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.

[14]  P. Zinzani,et al.  Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice , 2015, Leukemia & lymphoma.

[15]  T. Sher,et al.  Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type , 2015, Annals of Hematology.

[16]  M. Czuczman,et al.  A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Gascoyne,et al.  Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Staudt,et al.  A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL , 2014 .

[19]  T. Petrella,et al.  High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. , 2014, JAMA dermatology.

[20]  V. Pavone,et al.  Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. , 2014, The Lancet. Oncology.

[21]  O. Dereure,et al.  Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. , 2014, JAMA dermatology.

[22]  T. Petrella,et al.  Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma , 2014, Modern Pathology.

[23]  R. Bouabdallah,et al.  Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma , 2014, Leukemia & lymphoma.

[24]  F. Foschi,et al.  Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type , 2014, Annals of Hematology.

[25]  S. Pileri,et al.  Long‐term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B‐cell lymphoma patients , 2013, Hematological oncology.

[26]  R. Chopra,et al.  Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression , 2012, British journal of haematology.

[27]  D. Cappellen,et al.  MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. , 2012, The Journal of investigative dermatology.

[28]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[29]  S. Pileri,et al.  Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. , 2011, Clinical lymphoma, myeloma & leukemia.

[30]  M. Czuczman,et al.  Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype , 2011, Cancer.

[31]  H. Schulze,et al.  Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. , 2011, Acta dermato-venereologica.

[32]  U. Jäger,et al.  Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response , 2011, British journal of haematology.

[33]  J. Vose,et al.  An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[35]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[36]  L. Pasqualucci,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[37]  T. Petrella,et al.  Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. , 2009, Archives of dermatology.

[38]  I. Lossos,et al.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Angelica Selim,et al.  TNM Classification System for Primary Cutaneous Lymphomas , 2008 .

[40]  R. Dummer,et al.  European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. , 2008, Blood.

[41]  B. Cheson,et al.  Lenalidomide for the treatment of B-cell malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Willemze,et al.  Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. , 2007, Archives of dermatology.

[43]  T. Petrella,et al.  Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. , 2007, Archives of dermatology.

[44]  C. Meijer,et al.  Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Leonard,et al.  Proteasome inhibition with bortezomib: A new therapeutic strategy for non‐Hodgkin's lymphoma , 2006, International journal of cancer.

[47]  C. Meijer,et al.  Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma , 2006, Modern Pathology.

[48]  C. Massone,et al.  Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. , 2005, Blood.

[49]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[50]  T. Petrella,et al.  Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. , 2004, Blood.

[51]  D Machin,et al.  A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer , 2002, British Journal of Cancer.

[52]  R. Willemze,et al.  Primary Cutaneous Large B-Cell Lymphomas of the Legs: A Distinct Type of Cutaneous B-Cell Lymphoma With an Intermediate Prognosis , 1996 .

[53]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[54]  C. Schmidt,et al.  Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. , 2014, The Journal of investigative dermatology.

[55]  M. Bagot,et al.  Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients. , 2010, Archives of dermatology.